Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Mallinckrodt
Moodys
Baxter
Merck

Last Updated: October 2, 2022

Investigational Drug Information for BRL-50481


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for BRL-50481?

BRL-50481 is an investigational drug.

There have been 6 clinical trials for BRL-50481. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2000.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Leukemia. The leading clinical trial sponsors are GlaxoSmithKline, Directorate General of Health Services of Bangladesh, and International Centre for Diarrhoeal Disease Research, Bangladesh.

Recent Clinical Trials for BRL-50481
TitleSponsorPhase
Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB SymptomsChang Gung Memorial HospitalN/A
A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic LeukemiaCelgenePhase 1/Phase 2
A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic LeukemiaMundipharma Research GmbH & Co KGPhase 1/Phase 2

See all BRL-50481 clinical trials

Clinical Trial Summary for BRL-50481

Top disease conditions for BRL-50481
Top clinical trial sponsors for BRL-50481

See all BRL-50481 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Mallinckrodt
Moodys
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.